Clinical trial · people

Setmelanotide: quality of life rose after 52 weeks in Bardet-Biedl

Checked against the paper Clinical trialPublished by PepVault

The takeaway

For people with Bardet-Biedl syndrome, this trial adds that a year on setmelanotide came with meaningful gains in self-reported quality of life, and in adults those gains moved with weight change.

Kind
Clinical trial
Studied in
People
Published
2023
Journal
Orphanet J Rare Dis

What they tested

The team asked whether health-related quality of life changed in children and adults with Bardet-Biedl syndrome, a rare genetic disease tied to constant hunger and severe early obesity, after 1 year of setmelanotide.

How the study was done

In a phase 3 trial, people with Bardet-Biedl syndrome and obesity received setmelanotide for 52 weeks. This analysis described changes in 9 patients under 18 and 11 adults who filled in quality of life questionnaires at the start of active treatment and at 52 weeks, without a comparison group.

A woman in glasses at a kitchen table with a laptop, a mug and her phone

Model. Individual results vary.

PepVault for iPhone

Taking setmelanotide? Keep your own record

Log each dose, your weight and how you feel, in one place.

Download on the App Store

7 days free on the yearly plan for new subscribers.

What they found

In those under 18, the PedsQL score (a pediatric quality of life questionnaire, where a 4.4-point change counts as meaningful) rose by a mean of +11.2. All 4 young patients whose scores showed impairment at the start improved by a clinically meaningful amount. In adults, the IWQOL-Lite score (a questionnaire on how weight affects daily life, where a 7.7 to 12-point change counts as meaningful) rose by a mean of +12.0, and 62.5% of the 8 adults with impaired scores at the start improved meaningfully. Among adults, the IWQOL-Lite score was significantly linked to how much their weight shifted in percent terms (P = 0.0037) and to the shift in BMI, a weight-for-height measure (P = 0.0098).

What it doesn’t show

This was a small group, and the results are descriptive with no placebo comparison, so they cannot show how much of the change came from the drug itself. Scores were self-reported or caregiver-reported, and only patients with data at both time points were included.

The paper

Forsythe et al. Quality of life improvements following one year of setmelanotide in children and adult patients with Bardet-Biedl syndrome: phase 3 trial results. Orphanet J Rare Dis. 2023.

The compound

More studies on Setmelanotide

Researched and drafted with AI, then checked claim by claim against the primary sources linked below by a separate review pass. Published by PepVault. Last reviewed . Spot an error? feedback@pepvault.app. How we research. This page reports one study; it is not medical advice.

Track it in the app

PepVault for iPhone

Taking setmelanotide? Keep your own record

Log each dose, your weight and how you feel, in one place.

Download on the App Store

7 days free on the yearly plan for new subscribers.

Explore the live demo